Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Dendritic cells boosted with mRNA form promising cancer immunotherapy

With its expertise in mRNA production and knowledge of the biology of dendritic cells, eTheRNA has developed TriMix, a new mRNA technology platfor…


Very promising cancer treatment: RNAi immunotherapy

RXi Pharmaceuticals was co-founded by Craig Mello, PhD, the co-recipient of the 2006 Nobel Prize in Medicine for the discovery of RNA interference…


Allogeneic CAR T-cells patented by Celyad

Celyad obtained a patent relating to allogeneic Chimeric Antigen Receptor (CAR) T-cells. CAR T-cells are T-cells, which are engineered to better r…

POPULAR TAGS

Biogazelle receives 1 million euro to develop cancer therapy

Written by DS on in the category news with the tags , .


Biogazelle today announced that it has received €1.1M in funding from the agency for Innovation by Science and Technology (IWT) in Flanders to leverage its cancer therapy development program, focused on silencing long non-coding RNAs (lncRNAs). 

CSO and co-founder Jo Vandesompele comments on the company’s focus on lncRNAs: "Biogazelle always had a special interest in the non-coding part of our transcriptome. Many non-coding RNA genes now appear to play an important role in various diseases. To better understand this, we have developed LNCarta, a proprietary database with predicted lncRNA functions. Further, unlike protein-coding mRNAs, lncRNAs have many features that make them excellent therapeutic targets. Their remarkable cell type specific expression is just one example, which helps in developing safe treatments with minimal side effects."

Vandesompele also emphasizes the large potential of targeting RNA molecules for cancer treatment: "RNA targeted therapy is one of the most promising therapeutic modalities emerging. We have successfully tested various RNA silencing technologies to inhibit lncRNAs. The first studies in scientific literature show promising potential for lncRNAs as anti-cancer therapy.’’

Biogazelle's cancer therapeutic program started last year with a €2M investment and the establishment of a new research infrastructure and multidisciplinary research team. The facility includes a state-of-the-art cell culture and functional genomics platform.

Read more about: , .

RELATED ARTICLES
Dendritic cells boosted with mRNA form promising cancer immunotherapy

With its expertise in mRNA production and knowledge of the biology of dendritic cells, eTheRNA has developed TriMix, a new mRNA technology platfor…


Very promising cancer treatment: RNAi immunotherapy

RXi Pharmaceuticals was co-founded by Craig Mello, PhD, the co-recipient of the 2006 Nobel Prize in Medicine for the discovery of RNA interference…


Allogeneic CAR T-cells patented by Celyad

Celyad obtained a patent relating to allogeneic Chimeric Antigen Receptor (CAR) T-cells. CAR T-cells are T-cells, which are engineered to better r…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Flanders.bio Turnstone V-Bio Ventures KU Leuven Janssen Itera Life Science GSK XpandInnovation Biowin UGent

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.